Table 2.
The analysis for lincRNA-ROR and the clinicopathological characteristics of patients with cancer.
| Pooled data | Test for heterogeneity | ||||||||
| Clinicopathological features | Number of studies | Number of case (n) | lincRNA-ROR high expression (n) | RR | 95% CI | P-value | Chi2 | P-value | I2 (%) |
| Age (<60 vs >60) | 9 | 794 | 408 | 0.93 | 0.81–1.07 | .310 | 7.50 | .484 | 0.0 |
| Gender (male vs female) | 14 | 1130 | 583 | 0.99 | 0.88–1.12 | .925 | 7.78 | .858 | 0.0 |
| Tumor size (cm) (>5 vs <5) | 5 | 425 | 224 | 1.82 | 1.10–3.04 | .021 | 22.42 | <.001 | 82.2 |
| Infiltration depth (T3/T4 vs T1/T2) | 4 | 309 | 165 | 1.32 | 0.87–2.00 | .197 | 10.57 | .014 | 71.6 |
| Differentiation (poor vs well/moderate) | 7 | 467 | 249 | 1.15 | 0.80–1.65 | .445 | 22.84 | .001 | 73.7 |
| TNM stage (III/VI vs I/II) | 10 | 968 | 504 | 1.55 | 1.29–1.88 | < .001 | 21.47 | .011 | 58.1 |
| Clinical stage (III/VI vs I/II) | 2 | 66 | 33 | 2.10 | 1.20–3.67 | .009 | 0.41 | .523 | 0.0 |
| Lymph metastasis (yes vs no) | 10 | 956 | 495 | 1.55 | 1.25–1.94 | < .001 | 24.51 | .004 | 63.3 |
| Metastasis (yes vs no) | 7 | 641 | 334 | 1.65 | 1.26–2.16 | < .001 | 16.98 | .009 | 64.7 |
| Vessel invasion (yes vs no) | 3 | 227 | 119 | 1.87 | 1.42–2.47 | < .001 | 0.54 | .763 | 0.0 |
| Serum CA19–9 (positive vs negative) | 3 | 200 | 106 | 0.84 | 0.63–1.12 | .241 | 1.48 | .477 | 0.0 |
| Serum CEA (positive vs negative) | 2 | 139 | 75 | 0.90 | 0.65–1.24 | .514 | 0.77 | .380 | 0.0 |
CI = confidence interval, RR = risk ratio.